Top Clean Energy Stocks To Own Right Now

Mention the word uranium and most likely weapons of mass destruction come to mind. While you can make plenty of jokes about investment returns in the event of nuclear war, choosing to diversify your portfolio with uranium mining stocks is certainly worth a closer look.

Azincourt Uranium Inc. (OTCBB: AZURF) (TSX: AAZ.V) the Canadian based resource company specializing in the strategic acquisition, exploration and development of uranium properties, recently announced that it has completed the acquisition of an option to gain an undivided 70-percent stake in a mining project in the Athabasca Basin of Saskatchewan. This allows the mining company to increase exploration and production mining in a region known to be rich in base minerals.

The significance of this is twofold: as climate change continues to be a global issue, the demand for clean energy is rising. And as demand rises, so too does the number of nuclear reactors under construction worldwide. In China alone there were 20 nuclear reactors under construction at the end of March, 2017.

Top Clean Energy Stocks To Own Right Now: Integrated Electrical Services Inc.(IESC)

Advisors’ Opinion:

  • [By Shane Hupp]

    Gendell Jeffrey L decreased its stake in shares of IES Holdings Inc (NASDAQ:IESC) by 0.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,319,064 shares of the technology company’s stock after selling 36,081 shares during the period. IES comprises 21.0% of Gendell Jeffrey L’s portfolio, making the stock its largest holding. Gendell Jeffrey L owned about 0.58% of IES worth $186,634,000 as of its most recent filing with the Securities & Exchange Commission.

Top Clean Energy Stocks To Own Right Now: Heron Therapeutics, Inc. (HRTX)

Advisors’ Opinion:

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Jason Hall, George Budwell, and Chuck Saletta]

    And while it may not always work out well to simply copy the moves other investors make, it can pay off to use their buying and selling moves as jumping-off points in your own research. We asked three real-world investors for their insight, and they wrote about two recent Buffett buys ofApple Inc.(NASDAQ:AAPL) andUSG Corporation(NYSE:USG), and a recent Baker Brothers buy ofHeron Therapeutics Inc(NASDAQ:HRTX).

  • [By George Budwell]

    As things stand now, Cara’s immediate future hinges directly on the strength of Korsuva’s late-stage results in both postoperative pain and CKD-associated pruritus. Having said that, I think investors should largely consider the drug’s postoperative pain indication as icing on the cake at this point. Heron Therapeutics’ (NASDAQ:HRTX)experimental pain medicine HTX-011, after all, appears to have a sizable advantage in terms of efficacy over Korsuva based on the trial data so far. And Heron is almost certainly going to beat Cara to market by several years as well, giving it a formidable first-mover advantage.

  • [By Chris Lange]

    Heron Therapeutics Inc. (NASDAQ: HRTX) shares saw a massive gain on Thursday after the company announced a few key developments. First, the firm provided positive results from its midstage trial, as well as a critical update from the U.S. Food and Drug Administration (FDA).

  • [By George Budwell]

    Shares of the commercial-stage biotech Heron Therapeutics (NASDAQ:HRTX) gained as much as 36.3% today on abnormally high volume. What triggered this massive surge higher?

  • [By Dan Caplinger]

    Thursday was a poor day on Wall Street, with major benchmarks giving up about 0.5%-1% across the board. Trade concerns remain the focal point for market participants, with the latest controversy over U.S. immigration policy posing a potential threat to relations with traditional American allies abroad as well. Even with worries on a big-picture level, some individual companies had good news that sent their shares higher. Stitch Fix (NASDAQ:SFIX), Barnes & Noble Education (NYSE:BNED), and Heron Therapeutics (NASDAQ:HRTX) were among the best performers on the day. Here’s why they did so well.

Top Clean Energy Stocks To Own Right Now: ZIOPHARM Oncology Inc(ZIOP)

Advisors’ Opinion:

  • [By George Budwell]

    Shares of the clinical-stage biotech Ziopharm Oncology (NASDAQ:ZIOP) rose by a healthy 16% last month,according toS&P Global Market Intelligence. What sparked this sizable rally?

  • [By Keith Speights]

    If you like putting money into the beaten-down stocks of clinical-stage biotechs, Ziopharm Oncology (NASDAQ:ZIOP) and Celldex Therapeutics (NASDAQ:CLDX) might warrant a look. Ziopharm’s share price has dropped more than 25% so far in 2018, while Celldex stock has plunged more than 80%.

  • [By Todd Campbell]

    It garnered a lot of attention in 2015 when Ziopharm (NASDAQ:ZIOP) announced it would use its “sleeping beauty” technology to improve upon chimeric antigen receptor T-cell therapies that it was developing. Then, its mosquitoes that are engineered so that they can’t reproduce and spread disease won investor interest during the Zika virus outbreak in 2015 and 2016.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Stellar Biotechnologies, Inc. (NASDAQ: SBOT) fell 42 percent to $2.25 in pre-market trading after dropping 31.45 percent on Thursday. Stellar Biotechnologies priced 2.075 million units at price of $2.65 per unit.
    Symantec Corporation (NASDAQ: SYMC) shares fell 25.2 percent to $21.82 in pre-market trading. Symantec reported better-than-expected earnings for its fourth quarter, but issued weak second-quarter guidance.
    AGM Group Holdings Inc. (NASDAQ: AGMH) shares fell 9.5 percent to $10 in pre-market trading after surging 7.79 percent on Thursday.
    ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) fell 8.9 percent to $4.11 in pre-market trading after the company posted wider-than-expected Q1 loss.
    Redfin Corporation (NASDAQ: RDFN) fell 8.6 percent to $21.00 in pre-market trading after reporting Q1 results.
    Geron Corporation (NASDAQ: GERN) fell 8.3 percent to $3.33 in pre-market trading. Geron posted a Q1 loss of $0.04 per share.
    Talend S.A. (NASDAQ: TLND) shares fell 6 percent to $56 in pre-market trading after reporting Q1 results.
    Flotek Industries, Inc. (NYSE: FTK) fell 5.4 percent to $3.54 in pre-market trading after dropping 2.35 percent on Thursday.
    Halozyme Therapeutics, Inc. (NASDAQ: HALO) fell 5.1 percent to $18.95 in pre-market trading after reporting Q1 results.
    Yelp Inc. (NYSE: YELP) shares fell 4.9 percent to $45.40 in pre-market trading. Yelp reported stronger-than-expected results for its first quarter on Thursday.
    Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares fell 3.3 percent to $7.50 in pre-market trading after dropping 4.32 percent on Thursday

Top Clean Energy Stocks To Own Right Now: SEACOR Holdings, Inc.(CKH)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Headlines about Seacor (NYSE:CKH) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Seacor earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the oil and gas company an impact score of 45.3315874804175 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

  • [By Stephan Byrd]

    State of Tennessee Treasury Department reduced its stake in shares of Seacor Holdings, Inc. (NYSE:CKH) by 9.5% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 11,943 shares of the oil and gas company’s stock after selling 1,254 shares during the period. State of Tennessee Treasury Department owned approximately 0.07% of Seacor worth $610,000 at the end of the most recent quarter.